These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 22361813)

  • 1. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
    Gaugler MN; Genc O; Bobela W; Mohanna S; Ardah MT; El-Agnaf OM; Cantoni M; Bensadoun JC; Schneggenburger R; Knott GW; Aebischer P; Schneider BL
    Acta Neuropathol; 2012 May; 123(5):653-69. PubMed ID: 22361813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
    Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
    Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
    Dusonchet J; Bensadoun JC; Schneider BL; Aebischer P
    Neurobiol Dis; 2009 Jul; 35(1):32-41. PubMed ID: 19348945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
    Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
    Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
    Andersson DR; Nissbrandt H; Bergquist F
    Eur J Neurosci; 2006 Jul; 24(2):617-24. PubMed ID: 16903863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
    Peneder TM; Scholze P; Berger ML; Reither H; Heinze G; Bertl J; Bauer J; Richfield EK; Hornykiewicz O; Pifl C
    Neuroscience; 2011 Apr; 180():280-92. PubMed ID: 21333719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated exposure to the herbicide atrazine alters locomotor activity and the nigrostriatal dopaminergic system of the albino rat.
    Rodríguez VM; Limón-Pacheco JH; Mendoza-Trejo MS; González-Gallardo A; Hernández-Plata I; Giordano M
    Neurotoxicology; 2013 Jan; 34():82-94. PubMed ID: 23123945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
    Andersson DR; Björnsson E; Bergquist F; Nissbrandt H
    Exp Neurol; 2010 Jan; 221(1):251-9. PubMed ID: 19944096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
    Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
    Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons.
    Ulusoy A; Björklund T; Buck K; Kirik D
    Neurobiol Dis; 2012 Sep; 47(3):367-77. PubMed ID: 22659302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
    Park SS; Schulz EM; Lee D
    Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
    Xilouri M; Brekk OR; Landeck N; Pitychoutis PM; Papasilekas T; Papadopoulou-Daifoti Z; Kirik D; Stefanis L
    Brain; 2013 Jul; 136(Pt 7):2130-46. PubMed ID: 23757764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.